S&P 500   4,242.81 (-1.06%)
DOW   33,143.18 (-0.87%)
QQQ   358.57 (-0.74%)
AAPL   172.18 (-0.90%)
MSFT   318.38 (-1.06%)
META   303.87 (-0.96%)
GOOGL   133.15 (-0.76%)
AMZN   126.23 (-2.49%)
TSLA   247.52 (-1.62%)
NVDA   446.65 (-0.26%)
NIO   8.57 (-2.50%)
BABA   83.97 (-2.96%)
AMD   102.23 (-1.01%)
T   14.67 (+0.00%)
F   12.11 (-1.62%)
MU   68.83 (+1.28%)
CGC   0.69 (-6.92%)
GE   108.67 (-0.11%)
DIS   80.87 (-0.98%)
AMC   8.12 (-0.37%)
PFE   33.88 (-0.18%)
PYPL   58.11 (-0.77%)
NFLX   385.92 (+1.47%)
S&P 500   4,242.81 (-1.06%)
DOW   33,143.18 (-0.87%)
QQQ   358.57 (-0.74%)
AAPL   172.18 (-0.90%)
MSFT   318.38 (-1.06%)
META   303.87 (-0.96%)
GOOGL   133.15 (-0.76%)
AMZN   126.23 (-2.49%)
TSLA   247.52 (-1.62%)
NVDA   446.65 (-0.26%)
NIO   8.57 (-2.50%)
BABA   83.97 (-2.96%)
AMD   102.23 (-1.01%)
T   14.67 (+0.00%)
F   12.11 (-1.62%)
MU   68.83 (+1.28%)
CGC   0.69 (-6.92%)
GE   108.67 (-0.11%)
DIS   80.87 (-0.98%)
AMC   8.12 (-0.37%)
PFE   33.88 (-0.18%)
PYPL   58.11 (-0.77%)
NFLX   385.92 (+1.47%)
S&P 500   4,242.81 (-1.06%)
DOW   33,143.18 (-0.87%)
QQQ   358.57 (-0.74%)
AAPL   172.18 (-0.90%)
MSFT   318.38 (-1.06%)
META   303.87 (-0.96%)
GOOGL   133.15 (-0.76%)
AMZN   126.23 (-2.49%)
TSLA   247.52 (-1.62%)
NVDA   446.65 (-0.26%)
NIO   8.57 (-2.50%)
BABA   83.97 (-2.96%)
AMD   102.23 (-1.01%)
T   14.67 (+0.00%)
F   12.11 (-1.62%)
MU   68.83 (+1.28%)
CGC   0.69 (-6.92%)
GE   108.67 (-0.11%)
DIS   80.87 (-0.98%)
AMC   8.12 (-0.37%)
PFE   33.88 (-0.18%)
PYPL   58.11 (-0.77%)
NFLX   385.92 (+1.47%)
S&P 500   4,242.81 (-1.06%)
DOW   33,143.18 (-0.87%)
QQQ   358.57 (-0.74%)
AAPL   172.18 (-0.90%)
MSFT   318.38 (-1.06%)
META   303.87 (-0.96%)
GOOGL   133.15 (-0.76%)
AMZN   126.23 (-2.49%)
TSLA   247.52 (-1.62%)
NVDA   446.65 (-0.26%)
NIO   8.57 (-2.50%)
BABA   83.97 (-2.96%)
AMD   102.23 (-1.01%)
T   14.67 (+0.00%)
F   12.11 (-1.62%)
MU   68.83 (+1.28%)
CGC   0.69 (-6.92%)
GE   108.67 (-0.11%)
DIS   80.87 (-0.98%)
AMC   8.12 (-0.37%)
PFE   33.88 (-0.18%)
PYPL   58.11 (-0.77%)
NFLX   385.92 (+1.47%)
NASDAQ:MYMD

MyMD Pharmaceuticals (MYMD) Stock Forecast, Price & News

$0.57
-0.02 (-2.99%)
(As of 10:08 AM ET)
Compare
Today's Range
$0.56
$0.58
50-Day Range
$0.47
$1.87
52-Week Range
$0.45
$3.30
Volume
91,968 shs
Average Volume
569,072 shs
Market Capitalization
$25.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

MYMD stock logo

About MyMD Pharmaceuticals (NASDAQ:MYMD) Stock

MyMD Pharmaceuticals, Inc. is a pioneering biopharmaceutical company focused on developing personalized medicine and therapeutics. The company's mission is to improve patient outcomes and quality of life by advancing innovative treatments that target the underlying causes of diseases. MyMD Pharmaceuticals is headquartered in Baltimore, Maryland.

The company is dedicated to discovering and developing transformative therapies that address various medical conditions, including autoimmune diseases, age-related diseases, and neurological disorders. MyMD Pharmaceuticals leverages its proprietary drug discovery platform, called MYMD-1, which combines genomics, artificial intelligence, and big data analytics to identify personalized treatment options for patients.

MyMD Pharmaceuticals is led by a highly experienced management team with a strong track record in the pharmaceutical industry. Dr. Christopher Chapman, Chief Executive Officer and Chairman has over 20 years of experience in drug discovery and development. He previously served in leadership roles at renowned biopharmaceutical companies, leading successful drug discovery programs.

MyMD Pharmaceuticals has shown steady revenue growth over the past few years. MyMD has yet to achieve profit, but its net loss numbers have decreased as it strides toward profitability. It is important to note that MyMD Pharmaceuticals is in early commercialization as a research-focused biopharmaceutical company. Thus its financials should be evaluated with a long-term perspective.

MyMD Pharmaceuticals' valuation metrics, such as the price-to-earnings and price-to-book ratios, should be considered in the context of its industry peers. The company's valuation reflects market expectations for its potential and future prospects, considering the inherent risks associated with drug development.

MyMD Pharmaceuticals operates in the highly competitive biopharmaceutical industry, which is characterized by rapid advancements in scientific research, regulatory challenges, and evolving market dynamics. The personalized medicine sector, in particular, offers significant growth potential as it aims to provide targeted therapies based on individual patient characteristics.

The company's competitive positioning lies in its proprietary MYMD-1 platform, which enables the identification of personalized treatment options. This positions MyMD Pharmaceuticals at the forefront of personalized medicine, with the potential to disrupt traditional disease treatment approaches.

MyMD Pharmaceuticals has identified several growth opportunities to capitalize on its scientific expertise and innovative drug discovery platform. The company plans to advance its lead drug candidates into clinical trials, targeting indications with significant unmet medical needs. Completing these trials could pave the way for regulatory approvals and subsequent commercialization.

Additionally, MyMD Pharmaceuticals aims to expand its pipeline through strategic collaborations, licensing agreements, and acquisitions. By partnering with academic institutions, research organizations, and other biopharmaceutical companies, MyMD Pharmaceuticals can access additional resources, expertise, and potential synergies to accelerate the development and commercialization of its therapies.

The company sees opportunities for geographic expansion into international markets. By seeking regulatory approvals in key regions, MyMD Pharmaceuticals can broaden its reach and address a larger patient population.

As with any biopharmaceutical company, MyMD Pharmaceuticals faces several risks and challenges that could impact its operations and financial performance. 

The success of drug candidates depends on the outcome of clinical trials. Unfavorable results or safety concerns could lead to setbacks, delays, or discontinuation of development programs.

The company operates in a highly regulated industry, and obtaining regulatory approvals is a critical milestone. Changes in regulatory requirements or delays in the approval process could affect the timeline and cost of bringing therapies to market.

The protection of intellectual property is crucial in the biopharmaceutical industry. MyMD Pharmaceuticals relies on patents and trade secrets to safeguard its proprietary technologies. Any infringement on intellectual property or challenges to patent validity could have significant consequences.

The company faces competition from established pharmaceutical companies, biotech startups, and academic institutions. Competitors may have more significant financial resources, an established market presence, or access to complementary technologies.

The successful commercialization of therapies depends on market acceptance and adoption by healthcare providers, payers, and patients. Factors such as pricing, reimbursement, and competition from existing treatment options can influence market penetration.

MYMD Price History

MYMD Stock News Headlines

The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
Healthcare & Pharmaceuticals
MyMD Pharmaceuticals, Inc. (MYMD)
See More Headlines
Receive MYMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MyMD Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MYMD Company Calendar

Last Earnings
8/14/2023
Today
10/02/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MYMD
Employees
9
Year Founded
N/A

Profitability

Net Income
$-15,200,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.37 per share

Miscellaneous

Free Float
43,748,000
Market Cap
$26.28 million
Optionable
Not Optionable
Beta
2.27
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Christopher C. Chapman Jr. (Age 70)
    M.D., Pres, Chief Medical Officer & Director
    Comp: $261.83k
  • Dr. Adam Kaplin M.D. (Age 56)
    Ph.D., Chief Scientific Officer
    Comp: $353.73k
  • Mr. Paul M. Rivard Esq. (Age 52)
    Chief Legal Officer
    Comp: $188.24k
  • Mr. Ian Rhodes CPA (Age 50)
    Interim Chief Financial Officer
  • Dr. Jenna Brager M.S.
    Ph.D., R.N., Exec. VP of Drug Devel.













MYMD Stock - Frequently Asked Questions

How have MYMD shares performed in 2023?

MyMD Pharmaceuticals' stock was trading at $1.15 at the start of the year. Since then, MYMD shares have decreased by 49.1% and is now trading at $0.5850.
View the best growth stocks for 2023 here
.

When is MyMD Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our MYMD earnings forecast
.

How were MyMD Pharmaceuticals' earnings last quarter?

MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) posted its quarterly earnings data on Monday, August, 14th. The company reported ($0.15) earnings per share (EPS) for the quarter.

What ETFs hold MyMD Pharmaceuticals' stock?

ETFs with the largest weight of MyMD Pharmaceuticals (NASDAQ:MYMD) stock in their portfolio include Global X Cannabis ETF (POTX).Cambria Cannabis ETF (TOKE).

What is MyMD Pharmaceuticals' stock symbol?

MyMD Pharmaceuticals trades on the NASDAQ under the ticker symbol "MYMD."

How do I buy shares of MyMD Pharmaceuticals?

Shares of MYMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MyMD Pharmaceuticals' stock price today?

One share of MYMD stock can currently be purchased for approximately $0.59.

How much money does MyMD Pharmaceuticals make?

MyMD Pharmaceuticals (NASDAQ:MYMD) has a market capitalization of $26.28 million. The company earns $-15,200,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis.

How can I contact MyMD Pharmaceuticals?

MyMD Pharmaceuticals' mailing address is 855 N. WOLFE STREET, BALTIMORE MD, 21205. The official website for the company is www.mymd.com. The company can be reached via phone at 856-848-8698, via email at investors@akersbio.com, or via fax at 856-848-0269.

This page (NASDAQ:MYMD) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -